Kornimate/medical-research-clean huggingface dataset:
effect of lifestyle intervention on mobilization of fat storage and iron deposition in obesity

Conditions: Liver Fat; Fertility Disorders; Life Style, Healthy; Glucose Metabolism Disorders (Including Diabetes Mellitus)

Summary: the goal of this clinical trial is to learn if calorie-restricted balanced diet could uniquely influence various fat storage pools and iron deposition and explore the relationships between fat or iron deposition loss in specific locations and glucose metabolism. the main questions it aims to answer are: after lifestyle intervention, which part of the body shows the fastest fat mobilization? which part shows the slowest fat mobilization? which area's fat mobilization is most related to the alleviation of glucose metabolism? is there a relationship between the fat deposition in organs and the iron deposition in organs? researchers will compare the liver fat, pancreatic fat, visceral fat, subscutaneous fat, liver and pancrease iron depositon after lifestyle intervention using self pre-and post-control . participants will: receive the lifestyle intervention in outpatient. visit the clinic once after 6 months for checkups and tests. keep a diary of their diet.

fat mobilization status is assessed using magnetic resonance, while the relief of glucose metabolism is determined based on the results of the ogtt before and after life style intervention.

Eligibility criteria:
inclusion criteria: * age between 18 and 70 years * have a bmi greater than 28.0 kg/m2 * exhibit abdominal obesity, defined as a waist circumference of at least 90 cm for men and 85 cm for women * willing to undergo a 6-month lifestyle intervention exclusion criteria: * for newly diagnosed patients with type 2 diabetes: those with fasting blood glucose ≥ 11.1 mmol/l, random blood glucose ≥ 16.7 mmol/l, or hba1c ≥ 9.0%, or those exhibiting significant hyperglycemic symptoms, who need to start antidiabetic medication treatment immediately; * a prior history of pancreatic diseases; * combination of drug-induced hepatitis, autoimmune hepatitis, and viral hepatitis; * with a definitive diagnosis of diabetes who have already started medication treatment; * severe complications from type 2 diabetes or other significant diseases; * usage of drugs affecting body weight, insulin sensitivity, or metabolic-associated fatty liver disease in the past three months (such as insulin, glucocorticoids, thiazolidinediones, metformin, sglt-2 inhibitors, or glp-1 receptor agonists); * with malignant tumors; * acute or chronic infection; * with elevated transaminase levels of unknown cause; * hemochromatosis; * with iron deficiency anemia who are receiving iron supplementation; * who have donated blood or received a transfusion within the past six months; * who have experienced cardiovascular events within the past six months; * with acute or chronic blood loss; * alcohol dependence, defined as ethanol intake exceeding 140 g/week for men and 70 g/week for women； * pregnant and lactating women.
diagnosing adverse drug reactions registry

Conditions: Genetics of Drug Metabolism

Summary: this multicenter registry is to assess whether the use of pharmacogenomic data results in a meaningful change in a subject's drug or dose regimen. in addition, the registry will evaluate the relationship between adverse drug reactions (adr) and genotype and assess resource utilization (emergency department visits and hospitalizations) associated with adr.


Eligibility criteria:
inclusion criteria: * subject has care coordinated at the treating physician's outpatient clinic; * subject has provided written informed consent; * subject is taking at least three (3) regularly scheduled medications, excluding as needed (prn) medications, over the counter medications and nutritional supplements; two (2) of which are known to be affected by genetic allelic variation. * subject's treating physician has a clinical suspicion that the subject is experiencing adverse signs or symptoms related to a prescribed medication or is not achieving the intended effect from the medication. exclusion criteria: * subject has a history of chronic renal dysfunction, chronic kidney disease stage 4 or 5; * subject has a history of abnormal hepatic function within the last 2 years (inr \>1.2 not attributable to anticoagulant medications, ast (aspartate aminotransferase) or alt (alanine aminotransferase) \>1.5x normal, or suspected cirrhosis); * subject has a history of malabsorption (short gut syndrome); * subject has a history of any gastric or small bowel surgery; * subject is currently hospitalized; * subject is currently being treated with intravenous medication; * subject underwent prior pharmacogenomic testing with results reported within the last 12 months. subjects may be eligible within 60 days from the date of pharmacogenomic testing.

Keywords: adverse drug reactions emergency department visits hospitalizations pharmacogenomic
aromatase inhibitor-associated musculoskeletal symptoms in non-metastatic, post menopausal breast cancer patients

Conditions: Breast Cancer

Summary: the purpose of this study is to compare pre and post aromatase inhibitor (ai) treatment serological markers of inflammation and assess for correlation with ai-ms.


Eligibility criteria:
inclusion criteria: * women 18 years and older with non-metastatic hormone receptor (er and/or pr) positive breast cancer who are eligible for and planning on starting treatment with an ai within one month of signing consent. * postmenopausal, defined as at least one of the following: a) amenorrhea for at least 12 months b) prior bilateral oophorectomy at least 2 years prior to trial registration. exclusion criteria: * history of autoimmune connective tissue disease, such as rheumatoid arthritis, lupus, or other autoimmune conditions affecting joints. * treatment with steroid (for any condition, except for chemotherapy premedication) within 30 days of trial registration. * prior treatment with an ai (patients previously or currently on tamoxifen are eligible as long as patients are off tamoxifen for 2 weeks prior to baseline blood draw) * active or ongoing infection * known metastatic disease * known history of hiv or hepatitis infections * ongoing radiation therapy (radiation must have been completed 2 weeks prior to starting treatment with an ai) * non-invasive (dcis, lcis) cancer only (no diagnosis of invasive cancer) * pregnant or lactating * unable to speak, read, and write in english

Keywords: post menopausal breast cancer
phase 1/2 dose escalation study in patients with relapsed or refractory waldenstrom's macroglobulinemia

Conditions: Waldenstrom's Macroglobulinemia

Summary: recent reports have identified a specific oncogenic mutation l265p of the myd88 gene in approximately 90% of the patients with waldenström's macroglobulinemia. myd88 is a key linker protein in the signaling pathway of toll like receptors (tlrs) 7, 8, and 9, and imo-8400 is an oligonucleotide specifically designed to inhibit tlrs 7,8, and 9. the scientific hypothesis for use of imo-8400 to treat patients with waldenström's macroglobulinemia depends on the inhibition of mutant myd88 signaling in the tlr pathway, thereby interrupting the proliferation of cell populations responsible for the propagation of the disease.

eligible subjects will be enrolled and assigned to escalating dose cohorts. treatment will be administered by subcutaneous injection.

Eligibility criteria:
inclusion criteria: patients must have a diagnosis of relapsed waldenstrom's macroglobulinemia. in addition to the above, key inclusion and exclusion criteria are listed below. inclusion criteria: 1. at least 18 years of age. 2. agree to use contraception 3. hemoglobin ≥ 7.5 g/dl, - absolute neutrophil count ≥ 1.0 x 109/l (1000/mm3), - platelets ≥ 50,000/μl exclusion criteria: 1. is nursing or pregnant 2. has bmi \> 34.9 kg/m2. 3. has a positive test for human immunodeficiency virus (hiv-1 or -2) hepatitis c virus (hcv) or hepatitis b surface antigen (hbsag). 4. receiving chronic systemic corticosteroid therapy \> 20 mg of prednisone daily. 5. being treated with other anti-cancer therapies (approved or investigational). 6. has, at the initiation of study drug, received cytotoxic chemotherapy or a bruton's tyrosine kinase (btk)-inhibitor (e.g. ibrutinib) within the past 3 weeks or rituximab within the past 2 months 7. has an active infection requiring systemic antibiotics. 8. has had surgery requiring general anesthesia within 4 weeks of starting the study. 9. has autoimmune cytopenia (anemia, thrombocytopenia, leukopenia). 10. has heart failure of class iii or iv. 11. has sensory or motor neuropathy limiting daily activities.
apr-548 in combination with azacitidine for the treatment of tp53 myelodysplastic syndromes (mds)

Conditions: MDS; Myelodysplastic Syndromes

Summary: phase 1 study evaluating the safety and efficacy of apr-548 in combination with azacitidine for the treatment of tp53-mutant myelodysplastic syndromes.

open-label first-in-human (fih) phase 1 clinical trial assessing the safety, pharmacokinetics (pk), and clinical activity of orally (p.o.) administered apr-548 alone and in combination with azacitidine for the treatment of tp53-mutant myelodysplastic syndromes (mds).

Eligibility criteria:
inclusion criteria: 1. provision of signed and dated, written informed consent prior to any study specific procedures. 2. documented diagnosis of tp53-mutant mds, according to who criteria that is relapsed/refractory or previously untreated mds. 3. adequate organ function as defined by the following laboratory values: 1. creatinine clearance ≥60 ml/min (by cockcroft-gault method, appendix i), 2. total serum bilirubin ≤1.5 × upper limit of normal (uln) unless due to gilbert's syndrome or mds organ involvement, 3. alanine aminotransferase (alt) and aspartate aminotransferase (ast) ≤2.5 × uln, unless due to mds organ involvement. 4. age ≥18 years at the time of signing the informed consent form. 5. eastern cooperative oncology group (ecog) performance status of 0, 1 or 2 (appendix ii). 6. projected life expectancy of ≥12 weeks. 7. clear ocular media and adequate pupil dilation to permit fundus examination and retinal imaging. exclusion criteria: 1. cardiac abnormalities, which includes, but not limited to: 1. myocardial infarction within six months prior to enrollment 2. new york heart association class iii or iv heart failure or known lvef \<40% 2. concomitant malignancies or previous malignancies with less than a 1 year disease-free interval at the time of signing informed consent. 3. use of cytotoxic chemotherapeutic agents, or experimental agents for the treatment of mds within 14 days or 5 half-lives of the product (whichever is shorter) of the first day of study drug treatment. 4. prior exposure to eprenetapopt (apr-246). 5. a female subject who is pregnant or breast-feeding. 6. known history of human immunodeficiency virus (hiv), active hepatitis b or active hepatitis c infection. 7. malabsorption syndrome or other condition likely to affect gastrointestinal absorption of apr-548. 8. known history or current evidence of ocular disease in either eye
a study comparing radiofrequency ablation and hepatic resection for hepatocellular carcinoma

Conditions: Carcinoma, Hepatocellular

Summary: the purpose of this prospective randomized study is to compare the efficacy and safety of radiofrequency ablation and hepatic resection for small hepatocellular carcinomas with very homogeneous underlying conditions.


Eligibility criteria:
inclusion criteria: 1. age between 20 and 70 years 2. child-pugh class a (score 5-6) 3. single hepatocellular carcinoma 4. maximal diameter of the tumor from 2 to 4 cm when measured on mri or ct (the diameter on mri was measured prior to that on ct) 5. no previous treatment 6. platelet count \> 80,000/mm3 exclusion criteria: 1. hcc abutting main hepatic veins or the first branches of the main portal vein 2. hcc abutting vessels ≥ 0.5 cm
understanding immunity to the covid-19 vaccines

Conditions: COVID-19; Immunity; Vaccine

Summary: the purpose of this study is to test over time immunity to the covid-19 vaccines. adults who are receiving covid-19 vaccines will be invited to participate.


Eligibility criteria:
inclusion criteria: * adults who are receiving a covid-19 vaccine exclusion criteria: * patients with special risks attendant to venipuncture
phase ⅱ study of adductor canal block with hr18034 for postsurgical pain management

Conditions: Total Knee Arthroplasty

Summary: phase ⅱ, randomized, double-blind, comparator-controlled study to evaluate the efficacy, safety and pharmacokinetics of single injection adductor canal block with hr18034 for postoperative pain management compared with ropivacaine.


Eligibility criteria:
inclusion criteria: 1. able and willing to provide a written informed consent 2. scheduled to undergo primary unilateral total knee arthroplasty under general anesthesia. 3. male or female，aged 18-75 years inclusive 4. body mass index (bmi) 18-28 kg/m2 inclusive 5. american society of anesthesiologists (asa) physical status classification ⅰ\~ⅱ exclusion criteria: 1. subjects with deformity of the involving operative limb, or other neuropathy 2. subjects with a history of new myocardial infarction or unstable angina within 6 months prior to randomization; 3. subjects with a history of ischemic stroke or transient ischemic attack (tia) 4. subjects with a history of mental system diseases and cognitive dysfunction 5. combination of other pain conditions that may affect postoperative pain assessment 6. persistent or recurrent nausea and/or vomiting due to other etiologies, including, but not limited to gastric outlet obstruction, hypercalcemia, or active peptic ulcer 7. subjects with a history of deep vein thrombosis-related disease 8. clinically significant abnormal clinical laboratory test value 9. allergic to a drug ingredient or component 10. use of any of medications, which affect drug metabolism or analgesia evaluation, within 5 half-lives or as specified prior to the study surgical procedure 11. history of alcohol abuse or prescription and/or illicit drug abuse 12. subjects with special diets (including tobacco, grapefruit and caffeine) 13. pregnant or nursing women 14. no birth control during the specified period of time 15. participated in clinical trials of other drugs (received experimental drugs) 16. the inestigators determined that other conditions were inappropriate for participation in this clinical trial
assessment of lung perfusion in patients with chronic obstructive pulmonary disease using fd mri

Conditions: COPD

Summary: in the recent years a novel method for functional lung imaging called fourier decomposition mri (fd mri) has been introduced that allows for simultaneous assessment of regional lung perfusion and ventilation-related information without exposure to ionizing radiation or administration of intravenous or inhalational contrast agent. in this project, the investigators plan to investigate whether fourier decomposition (fd) mri is able to provide similar clinical information on regional lung perfusion as the standard methods spect/ct and dce mri in patients with copd.

in the recent years a novel method for functional lung imaging called fourier decomposition mri (fd mri) has been introduced that allows for simultaneous assessment of regional lung perfusion and ventilation-related information without exposure to ionizing radiation or administration of intravenous or inhalational contrast agent. in this project, the investigators plan to investigate whether fourier decomposition (fd) mri is able to provide similar clinical information on regional lung perfusion as the standard methods spect/ct and dce mri in patients with copd. as mri in patients with copd is particularly challenging due to the rarefication of lung parenchyma, the fd mri technique will be combined with an ultra-fast steady-state free precession (ufssfp) acquisition method for improved signal efficiency. the investigators ultimate goal is to provide a mean to predict and monitor the outcome of different therapies, such as medication, valves and surgery in copd patients without requiring ionizing radiation or administration of contrast agents. in the framework of this study, 30 patients with copd will be enrolled prospectively. the study participants will be recruited by the clinic for thoracic surgery at the university hospital basel among all patients undergoing lung perfusion scintigraphy with spect/ct for surgery planning. each participant will undergo one mri examination of 30 min containing non-contrast-enhanced (fd mri) and contrast-enhanced (dce mri) imaging studies of regional lung perfusion.

Eligibility criteria:
inclusion criteria: informed consent as documented by signature exclusion criteria: * known hypersensitivity or allergy to gd-based mri contrast agents. * patients with cardiac pacemakers, intra cranial clips, metallic foreign bodies\^or other not mrcompatible implants (e.g. pumps etc.). * renal failure or severely impaired kidney function (egfr \< 30 ml/min /1,73 m2) * known or suspected non-compliance, claustrophobia. * inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant. * epilepsy. * age \<18 years. * previous enrolment into the current study. * enrolment of the investigator, his/her family members, employees and other dependent persons.

Keywords: fd mri copd spect/ct dce mri
racial differences: nitric oxide(no) and endothelin-1(et-1) in preeclampsia (pree)

Conditions: Preeclampsia

Summary: the goal of this study is to examine the activation of markers of endothelial and cardiovascular dysfunctions, from women with high-risk pregnancies. information from this study will hopefully provide enough information to determine a link between race, the advent of high risk pregnancies and cardiovascular markers. with this information it might be possible to intervene with approved pharmacological treatments.


Eligibility criteria:
inclusion criteria: * african-american or caucasian * pregnant * between ages of 18 - 40 years of age exclusion criteria: * presence of a disease or condition which is not preeclampsia * drug or alcohol abuse during pregnancy * obesity
hypertrophic cardiomyopathy symptom release by bx1514m

Conditions: Hypertrophic Cardiomyopathy

Summary: hypertrophic cardiomyopathy (hcm) is the most frequent genetic cardiac disease characterized by an asymmetric hypertrophic. in two third of patients, an obstruction to blood ejection is observed within the left ventricle which is named left ventricular outflow tract obstruction (lvoto). this phenomenon can occur at rest or during exercise and is associated with symptoms such as dyspnea, dizziness or chest pain that can significantly limit day life adaptation. to now, medical or interventional treatments such as betablocacker, calcium blockers or septal alcoholisation or surgery present with a limited efficiency. recent studies from investigators group revealed new concepts about the role of venous return to the lvoto. therefore the investigators hypothesis that bx1514m generating a venous vascular constriction, could improve symptoms of hcm patients by reducing lvoto.


Eligibility criteria:
inclusion criteria: * patients with a typical or atypical hypertrophic cardiomyopathy (hcm) confirmed by imaging modalities (echo and mri) and/or genetic tests or a relative history of hcm * left ventricular obstruction during exercise on treadmill (above 50 mmhg) * positive response to leg lifting test (obstruction reduction above 20 mmhg) at rest or in early recovery phase * daily symptoms as shortness of breath during exercise (nyha2-3), non coronary chest pain, dizziness * correct ultrasound windows quality * sinus rhythm * optimal medical treatment * for women, pregnancy test or contraception * written consent form obtained exclusion criteria: * previous treatment by bx1514m * extra-cardiac pathology with life expectancy below than 1 year * no capability of consent form written * pregnancy women * secondary hypertension hypertrophy, secondary valvular disease hypertrophy * permanent atrial fibrillation * severe ventricular arrhythmia without implantable cardioverter defibrillator (icd) * severe coronary disease * severe non stabilized hypertension * severe cardiopathy (ejection fraction below 40% or demonstrated elevated end diastolic pressure or pulmonary pressure above 60 mmhg) * bradycardia * narrow angle glaucoma * vascular prethrombotic diseases * vascular spams * thyrotoxicosis * pheochromocytoma * severe renal failure (\<30ml/mn) * patients at risk of urinary retention secondary to prostatic severe disease * raynaud's disease * non selective monoamine oxidase inhibitors (maois), iproniazid, nialamide or ephedrine, methylphenidate, phenylephrine, pseudoephedrine or digitalic * procedures modifying the peripheral venous return * participation to other research protocol

Keywords: left ventricular obstruction
randomized controlled trial of a minimal versus extended internet-based intervention for problem drinkers

Conditions: Alcohol Consumption; Hazardous Alcohol Consumption

Summary: alcohol is one of the leading contributors to premature mortality and disability. most people with alcohol problems will never seek treatment. there is a need to develop alternate ways to help problem drinkers outside of formal treatment settings. one promising strategy is internet-based interventions for problem drinkers. the first randomized controlled trial found that the investigators could reduce alcohol consumption by about six drinks per week at a six-month follow-up using a minimal, personalized feedback internet-based intervention. the investigators second randomized trial demonstrated that an extended internet-based intervention that contained a range of cognitive-behavioural and relapse prevention tools could produce greater reductions in problem drinking compared to that provided by the same minimal intervention at a six-month follow-up. building upon this research, the current project will assess whether this extended internet-based intervention can have a sustained impact on problem drinking. specifically, the major objective of this project is to conduct a randomized controlled trial comparing the impact of an extended internet-based self-help intervention for problem drinkers to a minimal internet-based intervention in the general population of problem drinkers over a two year period. problem drinking participants will be recruited through media advertisements across canada and will be randomly assigned to the minimal or extended internet-based interventions. six-month, twelve-month and two-year drinking outcomes will be compared between experimental conditions. it is predicted that participants receiving the extended internet intervention will display sustained improved drinking outcomes compared to participants in the minimal internet intervention condition. this programmatic line of research will advance the science of internet-mediated intervention.


Eligibility criteria:
inclusion criteria:•resident of canada * 18 years of age or over * a score of 8 or over on the alcohol use disorders identification test (audit) * indicate an interest in receiving self-help materials * have home access to the internet * are willing to participate in follow-up at six month, twelve month and 2 year intervals exclusion criteria:none -